title: Prevalence of serum antibodies to LA-1 oncoprotein, herpes simplex virus type-2 glycoprotein and human papillomavirus type 16 transactivator (E2) protein among Indian women with cervical neoplasia.
abstract: Prevalence of serum antibodies to synthetic peptide to oncoprotein of LA-1 known as oncogene of herpes simplex virus type-2, herpes simplex virus type-2 glycoprotein-D as an determinant of viral pathogenicity and human papillomavirus type 16 transactivator E2 protein was studied among 46 Indian women with cervical neoplasia using immunoblot assay for HSV-2 gD glycoprotein and LA-1 antibodies as well as peptide ELISA assay to detect HPV16 E2 antibodies. The seropositivity to LA-1 oncoprotein was found to be high (61%) among patients with invasive cervical carcinoma as compared to 35% in various grades of cervical intraepithelial neoplasia (CIN) and 36% in normal control women. In contrast to this, a uniformly high frequency of antibody to HPV 16 E2 was observed among women with CIN (68%), normal healthy controls (50%) and invasive cervical carcinoma (43%). However, a low frequency of seropositivity (13%) to recombinant vaccinia virus HSV-2 gD protein was found among 15 tested sera each from group of women with various grades of CIN as well as invasive cervical carcinoma as compared to 28% among seven normal healthy control. A negative correlation of LA-1 and HPV16 E2 seropositivity on patient by patient comparison among CIN and invasive cervical carcinoma group was observed which is statistically significant (P = 0.019 for CIN; P = 0.038 for invasive cervical carcinoma). However, a positive correlation (P = 0.144) was found among normal control women. The study has shown a desirable serological marker of cervical neoplasia. This serological marker could be employed as a screening tool in conjunction with cytopathological screening to diagnose women harbouring LA-1 oncogene associated cervical lesions.
authors.affiliation: Institute of Cytology and Preventive Oncology, ICMR Maulana Azad Medical College, New Delhi, India. bksharma@icpoicmr.nic.ren.in
authors.forename: B K
authors.initials: BK
authors.lastname: Sharma
authors.forename: R
authors.initials: R
authors.lastname: Sharma
authors.forename: C C
authors.initials: CC
authors.lastname: Smith
authors.forename: L
authors.initials: L
authors.lastname: Aurelian
mesh_terms: D000328:Adult; D000912:Antibodies, Neoplasm / Q000097:blood*; D005260:Female; D006801:Humans; D007194:India / Q000453:epidemiology; D015513:Oncogene Proteins / Q000276:immunology*; D015995:Prevalence; D015534:Trans-Activators / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology*
chemical_list: D000912:Antibodies, Neoplasm; D015513:Oncogene Proteins; D015534:Trans-Activators; D014759:Viral Envelope Proteins; C040570:glycoprotein D-herpes simplex virus type 2